Lovastatin extended release: A review of its use in the management of hypercholesterolaemia

Drugs

Volumn 63, Issue 7, 2003, Pages 685-699

  Curran, Monique P ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ATORVASTATIN; CHOLESTEROL; CREATINE KINASE; CYCLOSPORIN; DRUG METABOLITE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDISPAN; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ABDOMINAL PAIN; AREA UNDER THE CURVE; ASTHENIA; ATHEROSCLEROSIS; BILIARY EXCRETION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG INDICATION; DRUG TOLERABILITY; DYSPEPSIA; FIRST PASS EFFECT; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; INSOMNIA; ISCHEMIC HEART DISEASE; LONG TERM CARE; MYALGIA; NAUSEA; REVIEW; SUSTAINED RELEASE FORMULATION;

ABSORPTION; ADMINISTRATION, ORAL; ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERCHOLESTEROLEMIA; LOVASTATIN;

AVES;

EID: 0037247889     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363070-00007     Document Type: Review

References (53)

1. Henwood JM, Heel RC. Lovastatin: a preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia. Drugs 1988 Oct: 36 (4): 429-54
2. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results, I: efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991 Jan; 151 (1): 43-9
3. TM (Lovastatin) extended-release tablets: US prescribing information. Andrx Laboratories, 2002
4. Andrx Laboratories, 2002. (Data on file)
5. Moghadasian MH. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Life Sci 1999; 65 (13): 1329-37
6. Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999 Dec; 84 (3): 413-28
7. White CM. Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation. J Clin Pharmacol 1999 Feb; 39: 111-8
8. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998 May 27; 279 (20): 1643-50
9. Lacoste L, Lam JY, Hung J, et al. Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995 Dec 1; 92 (11): 3172-7
10. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994 Mar; 89 (3): 959-68
11. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS): the MARS Research Group. Ann Intern Med 1993 Nov 15; 119 (10): 969-76
12. Furberg CD, Adams Jr HP, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events: Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994 Oct; 90 (4): 1679-87
13. Penny WF, Ben-Yehuda O, Kuroe K, et al. Improvement of coronary artery endothelial dysfunction with lipid-lowering therapy: heterogeneity of segmental response and correlation with plasma-oxidized low desity lipoprotein. J Am Coll Cardiol 2001 Mar 1; 37: 766-74
14. Aviram M, Hussein O, Rosenblat M, et al. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy. J Cardiovasc Pharmacol 1998 Jan; 31: 39-45
15. Kaczmarek D, Hohlfeld T, Wambach G, et al. The actions of lovastatin on platelet function and platelet eicosanoid receptors in type II hypercholesterolaemia: a double-blind, placebo-controlled, prospective study. Eur J Clin Pharmacol 1993; 45 (5): 451-7
16. Essig M, Vrtovsnik F, Nguyen G, et al. Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: role of geranylgeranylation and Rho proteins. J Am Soc Nephrol 1998 Aug; 9: 1377-88
17. Ridker PM, Rifai N, Miles JS, et al. Lovastatin 20-40 mg/day lowers high sensitivity C-reactive protein levels in AFCAPS/TexCAPS. Circulation 2000 Oct 31; 102 Suppl.: 833
18. Pietsch A, Erl W, Lorenz RL. Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. Biochem Pharmacol 1996 Aug 9; 52: 433-9
19. Mastroberardino G, Costa C, Gavelli MS, et al. Plasma cortisol and testosterone in hypercholesterolaemia treated with clofibrate and lovastatin. J Int Med Res 1989; 17 (4): 388-94
20. Segarra A, Chacon P, Vilardell M, et al. Prospective case control study to determine the effect of lovastatin on serum testosterone and cortisol concentrations in hyperlipidemic nephrotic patients with chronic renal failure. Nephron 1996; 73 (2): 186-90
21. Mortensen SA, Leth A, Agner E, et al. Dose-related decrease of serum coenzyme Q10 during treatment with HMG- CoA reductase inhibitors. Mol Aspects Med 1997; 18 Suppl.: S137-44
22. Laaksonen R, Ojala JP, Tikkanen MJ, et al. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1994; 46 (No. 4): 313-7
23. Buxbaum JD, Geoghagen NS, Friedhoff LT. Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Aβ peptide. J Alzheimers Dis 2001 Apr; 3 (2): 221-9
24. Friedhoff LT, Cullen EI, Geoghagen NS, et al. Treatment with controlled-release lovastatin decreases serum concentrations of human β-amyloid (Aβ) peptide. Int J Neuropsychopharmacol 2001 Jun; 4 (2): 127-30
25. Lamson M, Phillips G, Shen J, et al. Pharmacokinetics of lovastatin extended-release dosage form (Lovastatin XL) in healthy volunteers. Biopharm Drug Dispos 2002 May; 23 (4): 143-9
26. Sun JX, Niecestro R, Phillips G, et al. Comparative pharmacokinetics of lovastatin extended-release tablets and lovastatin immediate-release tablets in humans. J Clin Pharmacol 2002 Feb; 42 (2): 198-204
27. Davidson MH, Lukacsko P, Sun JX, et al. A multiple-dose pharmacodynamic, safety, and pharmacokinetic comparison of extended- and immediate-release formulations of lovastatin. Clin Ther 2002 Jan; 24 (1): 112-25
28. Lukacsko P, Sterman A, Walters E, et al. High-dose, extended-release lovastatin enhances efficacy [abstract no. P-424R plus poster]. 36th Annual Midyear Clinical Meeting of the American Society of Health-System Pharmacists (ASHP); 2001 Dec 2-6; New Orleans (LA)
29. Duggan DE, Chen IW, Bayne WF, et al. The physiological disposition of lovastatin. Drug Metab Dispos 1989; 17 (2): 166-73
30. Lamson MJ. Lukacsko P, Niecestro RM, et al. Pharmacokinetics and pharmacodynamics of extended-release lovastatin [abstract no. 52]. J Clin Pharmacol 2002; 42 (9): 1062
31. Lamson M, Niecestro R, Walters E, et al. Effects of food on the absorption of lovastatin following administration from an extended-release dosage form [abstract no. 56]. J Clin Pharmacol 2002; 42 (9): 1063
32. Germershausen JI, Hunt VM, Bostedor RG, et al. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochem Biophys Res Commun 1989 Feb 15; 158 (3): 667-75
33. Botti RE, Triscari J, Pan HY, et al. Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin Neuropharmacol 1991 Jun; 14 (3): 256-61
34. Duggan DE, Vickers S. Physiological disposition of HMG-CoA-reductase inhibitors. Drug Metab Rev 1990; 22 (4): 333-62
35. Desager JP, Horsmans Y. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin Pharmacokinet 1996 Nov; 31: 348-71
36. Crouse III JR, Lukacsko P, Niecestro R, et al. Dose response, safety, and efficacy of an extended-release formulation of lovastatin in adults with hypercholesterolemia. Am J Cardiol 2002 Jan 15; 89 (2): 226-9
37. Davidson MH, Lukacsko P, Sun JX, et al. The effect of dosing time on efficacy and safety of an extended-release formulation of lovastatin in patients with primary hypercholesterolemia. J App Research 2001; 1 (2): 123-9
38. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert. JAMA 1993 Jun 16; 269 (23): 3015-23
39. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel 111). JAMA 2001 May 16; 285 (19): 2486-97
40. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999 Aug 12; 341 (7): 498-511
41. Rich SJ, Niecestro R, Brett V. Comparison cost of statin therapy [abstract no. P-85E plus poster]. Proceedings of the American Society of Health-System Pharmacists 37th Midyear Clinical Meeting; 2002 Dec 8-12; Atlanta (GA)
42. Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 2002; 25 (9): 649-63
43. Illingworth DR. Management of hypercholesterolemia. Med Clin North Am 2000 Jan; 84 (1): 23-42
44. Menotti A, Blackburn H, Kromhout D, et al. Changes in population cholesterol levels and coronary heart disease deaths in seven countries. Eur Heart J 1997 Apr; 18 (4): 566-71
45. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 Nov 19; 344 (8934): 1383-9
46. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996 Oct 3; 335 (14): 1001-9
47. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998 Nov 5; 339 (19): 1349-57
48. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995 Nov 16; 333 (20): 1301-7
49. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998 May 27; 279 (20): 1615-22
50. Tolman KG. The liver and lovastatin. Am J Cardiol 2002 Jun 15; 89 (12): 1374-80
51. Ballantyne CM, McKenney J, Trippe BS. Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia. Am J Cardiol 2000 Oct 1; 86 (7): 759-63
52. Ballantyne CM, Pazzucconi F, Pintó X, et al. Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. Clin Ther 2001 Feb; 23 (2): 177-92
53. Olsson AG, Pauciullo P, Soska V, et al. Comparison of the efficacy and tolerability of fluvastatin extended- release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial. Clin Ther 2001 Jan: 23 (1): 45-61